





©AllinaHealthSystems 1










RhiG


Administer within 72 hourse of event
Some protection up to 13 days
Not effective once sensitization occurs


RhoGAM® (Kedrion Biopharma, Inc.) IM only
BayRho® (Bayer Corporation) IM only
WinRho SDF® (Cangene Corporation) IM or IV
Rhophylac® (CSL Behring) IM or IV




©AllinaHealthSystems 2


3







# Management of First Sensitized Pregnancy Monitoring for Fetal Anemia Critical titer Titer at which fetus is at risk of severe anemia Denotes when ultrasound should begin 1:16 for all except Kell 1:4 for Kell













### MIDWEST FETAL CARE CENTER **Intrauterine Transfusion** Children's. Alina Health® Setting In/close to OR Sedation anesthesia Prophylactic Abx, tocolysis Fetal Site · Placental cord insertion · Hepatic portion of the umbilical vein Free loop Intraperitoneal Intracardiac Medications Vecuronium 0.1ma/ka · Fentanyl 2mcg/kg Midwest Fetal Care Center | 21



# Intrauterine Transfusion Complications Fetal bradycardia 2% emergency cesarean Infection 0.3%/procedure PPROM 0.1%/procedure Bleeding, fetal needle injuries, arterial spasm, alloimmunization Delivery Last IUT at 34w6d 7-10 days of phenobarbital Delivery at 37-38 weeks C/sec for routine obstetric indications



### **Immunomodultaion**

MIDWEST FETAL CARE CENTER
Children's. Allina Health®

	Past	Treated
	pregnancy	pregnancy
Perinatal loss	7/9	0/9
GA at first IUT (wks)	22.3 <u>+</u> 3.1	24.2 <u>+</u> 3.3
Fetal Hct at first IUT	15.0 <u>+</u> 8.2%	23.2 <u>+</u> 5.5%

© 2017

Ruma et al. Am J Obstet Gynecol 2007;196:133e1-138e6 25


## The Future

MIDWEST FETAL CARE CENTER
Children's. Allina Health %

- Momenta developed a monoclonal antibody for the prevention of HDFN in patients with a high risk of developing HDFN early in pregnancy
- An open label interventional trial is ongoing in US, Canada, Europe, Israel, and Australia
- Primary outcome is proportion of live births at or after 32 weeks without IUT

@ 2017

17



# **Outcomes**

MIDWEST FETAL CARE CENTER
Children's. Allina Health %

- 491 fetuses with 1422 transfusions
  - Overall perinatal survival: 91%
  - Survival when hydrops present: 83%
  - Survival when hydrops not present: 95%

Lindenburg et al. BJOG 2013: 120:847-52 28

# **Neonatal Follow Up -HDFN**

MIDWEST FETAL CARE CENTER
Children's. Allina Health


## Immediate Neonatal Period

- · Risk of ongoing anemia
- Saade et al. Fetal Diagn Ther 1993:8:161-4
  - 36 infants
  - 50% required top up transfusions
  - Mean 38 days (range 20-68 days)
- Weekly Reticulocyte and Hct until stable/increasing x 2

### Long Term Follow Up

- LOTUS Trial
  - 291 children IUT's between 1988-2008
  - Overall neurodevelopmental impairment 4.8%
  - Cerebral Palsy 2.1%(Dutch baseline 0.7%)
  - Severe developmental delay 3.% (Dutch baseline 2.3%)

Lindenburg et al. Am J Obstet Gynecol 2012; 205:141.e1-8 29



© Allina Health Systems



©AllinaHealthSystems 6